Role of receptor tyrosine kinases in gastric cancer:: New targets for a selective therapy

被引：49
作者：
Becker, J. C.
Mueller-Tidow, C.
Serve, H.
Domschke, W.
Pohle, T.
机构：
[1] Univ Munster, Dept Med B, D-48129 Munster, Germany
[2] Univ Munster, Dept Med A, D-48129 Munster, Germany
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2006年 / 12卷 / 21期
关键词：
gastric carcinoma; EGFR; gefitinib; trastuzumab; cetuximab; imatinib; erlotinib; bevacizumab;
D O I：
10.3748/wjg.v12.i21.3297
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码：3297 / 3305
页数：9
相关论文
共 96 条
[41]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[42]   Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):: Superiority over single-agent receptor targeting [J].
Matar, P ;
Rojo, F ;
Cassia, R ;
Moreno-Bueno, G ;
Di Cosimo, S ;
Tabernero, J ;
Guzmán, M ;
Rodriguez, S ;
Arribas, J ;
Palacios, J ;
Baselga, J .
CLINICAL CANCER RESEARCH, 2004, 10 (19) :6487-6501
[43]  
McCarty MF, 2004, MOL CANCER THER, V3, P1041
[44]   Targeting the epidermal growth factor receptor for cancer therapy [J].
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :1S-13S
[45]   Reduced expression of epidermal growth factor receptor related protein in gastric cancer [J].
Moon, WS ;
Tarnawski, AS ;
Chai, J ;
Yang, JT ;
Majumdar, APN .
GUT, 2005, 54 (02) :201-206
[46]  
Moulder Stacy L, 2003, Clin Breast Cancer, V4, P142, DOI 10.3816/CBC.2003.n.020
[47]   Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations [J].
Mukohara, T ;
Engelman, JA ;
Hanna, NH ;
Yeap, BY ;
Kobayashi, S ;
Lindeman, N ;
Halmos, B ;
Pearlberg, J ;
Tsuchihashi, Z ;
Cantley, LC ;
Tenen, DG ;
Johnson, BE ;
Jänne, PA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16) :1185-1194
[48]   High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets [J].
Müller-Tidow, C ;
Schwäble, J ;
Steffen, B ;
Tidow, N ;
Brandt, B ;
Becker, K ;
Schulze-Bahr, E ;
Halfter, H ;
Vogt, U ;
Metzger, R ;
Schneider, PM ;
Büchner, T ;
Brandts, C ;
Berdel, WE ;
Serve, H .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1241-1249
[49]  
Nakazawa K, 2003, CANCER RES, V63, P8848
[50]   Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and getitinib (ZD1839, Iressa™) for disseminated peritoneal scirrhous gastric cancer [J].
Namiki, Y ;
Namiki, T ;
Yoshida, H ;
Date, M ;
Yashiro, M ;
Matsumoto, K ;
Nakamura, T ;
Yanagihara, K ;
Tada, N ;
Satoi, J ;
Fujise, K .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (06) :1545-1555
12345678910